The honest state of the evidence
Ibogaine has one of the most unusual evidence profiles in pharmacology. Decades of case reports, observational studies, and clinical experience consistently describe a compound with striking anti-addictive effects — particularly for opioid dependence — that no approved treatment replicates. And yet, as of 2026, only two randomised controlled trials have been completed. The gap between the experiential record and the formal clinical evidence base is vast.
This gap exists largely for structural reasons. Ibogaine's Schedule I classification in the United States made rigorous research legally difficult and commercially unattractive for decades. Most of the evidence that exists was gathered in treatment clinics operating outside formal research frameworks, by clinicians who were doing their best under difficult regulatory conditions but whose data does not meet the standards required for regulatory approval.
The result is a substance with an unusually strong observational signal and an unusually weak formal evidence base — a combination that makes it genuinely difficult to evaluate and easy to either overstate or dismiss, depending on which part of the record you choose to emphasise.
How to read this page
This page distinguishes between different levels of evidence: randomised controlled trials (the gold standard), systematic reviews of existing literature, observational studies and case series, and expert consensus. The strength of a claim depends significantly on which type of evidence supports it.
Where evidence is limited or conflicted, we say so directly. The goal is not to advocate for or against ibogaine — it is to give you the clearest possible picture of what is and is not known.
Evidence by condition
Ibogaine has been studied most extensively for opioid use disorder, but the research extends to other substance dependencies and, more recently, to PTSD and traumatic brain injury. The strength of evidence varies considerably across these areas.
Note: These ratings reflect the volume and quality of published clinical evidence as of 2026, not the likelihood of future confirmation. They should not be read as endorsements or dismissals.
Key studies
Opioid use disorder · Observational cohort
Alper et al. — Ibogaine in the treatment of narcotic withdrawal
A cohort of 33 patients treated with 6 to 29 mg/kg of ibogaine. Twenty-five showed resolution of opioid withdrawal signs within 24 to 72 hours post-treatment. One of the most frequently cited early clinical studies, though not a randomised controlled trial.
25 of 33 patients showed resolution of withdrawal signs within 72 hours
No control group; results cannot be attributed solely to ibogaine
One death occurred in the participant who received the highest dose
Opioid & cocaine use disorder · Clinical observation
Mash et al. — Ibogaine in the treatment of heroin withdrawal
27 patients treated with lower oral doses of 10–12 mg/kg. Significantly reduced objective opiate withdrawal scores at 36 hours post-treatment. Self-reports of decreased cocaine and opiate craving and alleviated depression. Effects appeared to persist at one-month follow-up.
Significant reduction in objective withdrawal scores at 36 hours
Self-reported reduction in craving and depression symptoms sustained at one month
Observational design; self-report measures subject to bias
PTSD · Traumatic brain injury · Prospective open-label study
Cherian et al. (Stanford) — Magnesium–ibogaine therapy in veterans with traumatic brain injuries (MISTIC)
Thirty male Special Operations Forces veterans with predominantly mild traumatic brain injury underwent the Stanford-designed MISTIC protocol at a supervised clinic in Mexico: oral ibogaine co-administered with intravenous magnesium sulfate specifically to guard against the QT-interval prolongation linked to ibogaine-related cardiac deaths. Participants were monitored continuously for 72 hours post-dose and assessed at baseline, immediately after treatment, and at one month using validated clinical scales.
Published in Nature Medicine in early 2024, the study reported large, statistically significant improvements in functioning, PTSD, depression, and anxiety at one month, with no serious or unexpected adverse events, including no clinically meaningful cardiac events. It remains the strongest available safety data for the magnesium co-administration approach, though the authors themselves called for controlled trials to confirm the findings.
Large, statistically significant improvements in disability, PTSD, depression, and anxiety scores at one month
No serious cardiac adverse events recorded, credited to magnesium co-administration protecting against QT prolongation
No randomisation or control group; contribution of non-drug elements (travel, coaching, group setting) cannot be isolated
Population (male combat veterans) may not generalise to broader groups
A July 2025 neuroimaging follow-up in Nature Mental Health, drawing on EEG and MRI data from the same cohort, linked the cognitive gains to measurable changes in brain activity, including increased theta-rhythm activity associated with improved executive function.
What the systematic reviews say
Two major systematic reviews — published in 2022 and 2023 — attempted to synthesise the full body of clinical evidence on ibogaine and noribogaine. Their conclusions are consistent and worth quoting carefully, because they represent the most rigorous summary of the field available.
Köck et al., Journal of Substance Abuse Treatment, 2022
Köck et al., 2022
This systematic review surveyed clinical trials and therapeutic applications of ibogaine across the published literature. It identified a consistent pattern of anti-addictive effects across opioid, cocaine, and alcohol use disorders, and noted that comorbid depression and trauma symptoms also showed improvement in a number of studies. Critically, it also documented the safety record — including deaths — and concluded that the risks were significant enough to require rigorous clinical oversight as a precondition for any legitimate use.
Mosca et al., 2023
The 2023 review reached similar conclusions: ibogaine and noribogaine show some potential in treating substance use disorders, particularly for opiate detoxification, but efficacy is unconfirmed and use carries significant cardiotoxic and mortality risks. The review noted that only two randomised controlled trials had been completed — a figure that highlights just how far the clinical evidence base lags behind the observational record and the public interest in the compound.
Research now underway
The regulatory and political developments of 2025 and 2026 have created conditions for a significant expansion of clinical research. The following table summarises the major initiatives underway or in planning as of mid-2026.
| Initiative | Focus | Status | Notes |
|---|---|---|---|
| Texas IMPACT Programme (UTHealth Houston / UTMB Health) | Addiction; traumatic brain injury; PTSD | Active | $50M awarded December 2025 by the Texas Health and Human Services Commission under Senate Bill 2308, to a ten-plus-institution consortium. Two-year multicentre trial; UTHealth Houston leads on addiction, UT Austin and Baylor College of Medicine on TBI. Goal: FDA-approved treatment pathway. |
| US Executive Order (18 April 2026) — agency review | Regulatory pathway; Right to Try access; priority review | Active | Directs the FDA to issue Priority Review Vouchers to Breakthrough Therapy–designated psychedelics and directs FDA/DEA to build a Right to Try pathway for ibogaine. Allocates $50M in federal funds to match state investment. |
| DemeRx IND — DMX-1001 (oral noribogaine) | Alcohol use disorder | Active | First FDA-cleared human trial of an ibogaine-class compound, cleared April 2026. Phase 1 underway; Phase 2 anticipated 2027. |
| Scottsdale Research Institute IND — Ibogaine HCl | PTSD; traumatic brain injury; opioid use disorder | Planned | IND submitted July 2026. If authorised by FDA and IRB, would be the first US clinical trial of ibogaine itself, rather than a derivative; Phase 1 targeted for early 2027. |
| Noribogaine RCTs (New Zealand / international) | Opioid use disorder | Planned | Noribogaine — ibogaine's active metabolite — may carry lower cardiac risk. Separate development pathway being pursued by several research groups outside the US. |
| Tabernanthalog & 18-MC analogues | Addiction; safety optimisation | Preclinical | Non-hallucinogenic, potentially non-cardiotoxic ibogaine derivatives. Promising in animal models. Human trials not yet begun. |
| PTSD & TBI follow-up studies | PTSD; traumatic brain injury | Planned | Building on the 2024 Stanford MISTIC results and the 2025 neuroimaging follow-up. Several groups working to design randomised trials with control conditions. |
What the evidence does not yet tell us
Honest engagement with the ibogaine evidence base requires being equally clear about what remains unknown. The following are the most significant gaps as of 2026.
Long-term efficacy
Most ibogaine studies measure outcomes at one month. A small number extend to six months. Virtually none have followed patients for a year or more. The question of whether ibogaine's effects on addiction persist, require reinforcement, or fade entirely over time is essentially unanswered.
Optimal dosing and protocols
Doses used across studies and clinics vary enormously — from 6 mg/kg to 29 mg/kg. The relationship between dose, therapeutic effect, and risk has not been systematically studied. There is no consensus on optimal dosing for any indication.
The role of set and setting
Ibogaine is rarely administered without some form of psychological support, integration work, or therapeutic context. It is genuinely unclear how much of the observed therapeutic effect is pharmacological and how much depends on the context of the experience. This is not a trivial question — it has significant implications for how any approved treatment would need to be structured.
Diverse populations
The majority of published ibogaine research involves adult men with opioid dependence or, more recently, male combat veterans. Evidence in women, adolescents, people with significant medical comorbidities, and people from diverse ethnic and cultural backgrounds is limited or absent.